Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Hanada, S. Suzuki, H. Uruga, H. Takaya, A. Miyamoto, N. Morokawa, A. Kurosaki, K. Kishi (Minato-ku, Japan). Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia. Eur Respir J 2012; 40: Suppl. 56, 4378

Member's Comments

No comment yet.

Related content which might interest you: Systemic corticosteroid for treating severe community-acquired pneumonia Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Efficacy of corticosteroids in hospital treated community-acquired pneumonia Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 Hospital-acquired pneumonia in patients receiving immunosuppressive therapy Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Ertapenem therapy for community-acquired pneumonia in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia Source: Eur Respir J 2011; 37: 36-41 Year: 2011 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Intravenous steroids in the treatment of community-acquired pneumonia (CAP) Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004 Efficacy and safety of stepwise therapy in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 377s Year: 2006 Oral antibiotics prior to hospitalisation for community-acquired pneumonia Source: Eur Respir J 2008; 31: 478-479 Year: 2008 Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial Source: Eur Respir J, 58 (2) 2002535; 10.1183/13993003.02535-2020 Year: 2021 Efficacy of α-tocoferol in the treatment of patients with pneumonia Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Outpatient treatment of community-acquired pneumonia in the elderly Source: Eur Respir J 2002; 20: Suppl. 38, 355s Year: 2002